Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65-Reference-Cited by-同舟云学术

Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65

Published:2024-06-26 Issue:8 Volume:13 Page:1789-1805
ISSN:2193-8229
Container-title:Infectious Diseases and Therapy
language:en
Short-container-title:Infect Dis Ther

Author:

Buynak Robert,Cannon Kevin,DeAtkine David,Kirby John,Usdan Lisa^ORCID,Bhavsar Amit^ORCID,Gérard Catherine,Kuznetsova Anastasia,Jayadev Amulya,Amare Hiwot^ORCID,Valenciano Sofia^ORCID,Meyer Nadia

Funder

GSK

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40121-024-00985-4.pdf

Reference40 articles.

1. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol. 2013;45(3):331–79. https://doi.org/10.1007/s12016-013-8368-9.

2. Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment. Infect Dis Ther. 2021;10(Suppl 1):47–60. https://doi.org/10.1007/s40121-020-00383-6.

3. Chatterjee A, Mavunda K, Krilov LR. Current state of respiratory syncytial virus disease and management. Infect Dis Ther. 2021;10(Suppl 1):5–16. https://doi.org/10.1007/s40121-020-00387-2.

4. Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64. https://doi.org/10.1016/S0140-6736(22)00478-0.

5. Simoes EAF. Respiratory syncytial virus disease in young children and older adults in europe: a burden and economic perspective. J Infect Dis. 2022;226(Suppl 1):S1–9. https://doi.org/10.1093/infdis/jiac252.